Ecopirin

Quick links to important sections

Ecopirin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ecopirin

Property Description
Active ingredient Aspirin (Acetylsalicylic Acid)
Form Enteric-coated tablet (Oral dosage form)
Pharmacological class Antiplatelet agent and NSAID
General purpose Maintaining free blood flow (reducing platelet aggregation)
Origin Synthetic (Acetyl derivative of salicylic acid)

Ecopirin: Definition and Pharmacological Classification

Ecopirin is a single-ingredient pharmaceutical product containing the active substance Aspirin, which is chemically known as Acetylsalicylic Acid (ASA). This compound is a synthetic derivative, categorized as both a member of the Non-Steroidal Anti-Inflammatory Drug (NSAID) class and, more importantly for its specialized use, as an Antiplatelet agent. This classification means the medicine's core function is dedicated to modulating how blood cells interact. The therapeutic effect of inhibiting platelet function is clinically recognized for its role in long-term circulatory support.

Composition, Form, and Unique Preparation (Enteric-Coated)

Ecopirin is administered as an oral dosage form, specifically an enteric-coated tablet, a key feature that differentiates it from standard Aspirin formulations. This distinctive coating is a protective layer designed to resist dissolution in the acidic gastric environment, ensuring the Acetylsalicylic Acid is not released until the tablet passes into the small intestine. This unique preparation is utilized to reduce direct irritation of the gastric mucosa (stomach lining), a common concern with orally administered non-coated forms of ASA.

Primary Purpose and Core Antiplatelet Action

The primary purpose of this preparation is intrinsically linked to its essential function as an Antiplatelet agent, where it helps ensure the free flow of blood throughout the body. The drug works by acting on platelets to reduce their capacity for aggregation, or "stickiness." This action, achieved via the irreversible inhibition of the cyclooxygenase (COX-1) enzyme, is the focus of its specialized formulation. By preventing this enzyme from functioning, Ecopirin consistently helps promote smooth and consistent blood circulation, a primary general benefit.

Regulatory References

  1. NIH Review

What side effects are possible with Ecopirin?

Possible Side Effects and Safety Information

The safety profile of Ecopirin, which contains acetylsalicylic acid, is characterized primarily by risks related to Gastrointestinal Disorders and Bleeding Tendencies, classified by regulatory authorities based on frequency.

Adverse Reactions by Frequency

Classification Examples of Reactions
Common Dyspepsia, nausea, vomiting, gastrointestinal pain, mild gastrointestinal blood loss (may lead to iron deficiency anemia).
Uncommon Hypersensitivity reactions (urticaria, angioedema), hemorrhage (such as nosebleeds, gum bleeding, hematoma).
Rare Gastrointestinal hemorrhage (overt or occult), serious gastrointestinal bleeding, cerebral hemorrhage (especially with uncontrolled hypertension), severe hypersensitivity reactions (anaphylactic shock), Reye's Syndrome in children.
Very Rare Severe bleeding events, severe skin reactions (e.g., Stevens-Johnson syndrome).

Serious and Population-Specific Safety Concerns

Serious Adverse Reactions documented in official sources include Gastrointestinal Hemorrhage, Cerebral Hemorrhage, and Anaphylactic Shock. These define the most critical, though low-frequency, risks that require urgent medical attention.

Population-Specific Restrictions: Ecopirin is Contraindicated in the third trimester of pregnancy due to potential harm to the fetus and complications during delivery. Furthermore, its use is strictly restricted in children and adolescents with viral infections due to the risk of Reye's Syndrome, a rare but life-threatening condition. The risk of bleeding and gastrointestinal irritation is considered to be dose-dependent.

Ecopirin is also Contraindicated in patients with a known history of bleeding disorders, active gastrointestinal ulcers, severe kidney or liver failure, or severe, uncontrolled heart failure. Caution is noted for use in patients with a history of asthma or allergies.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediately call a poison control center or doctor for any suspected overdose, even if no signs or symptoms are present. If the person has collapsed, had a seizure, or is having trouble breathing, immediately call emergency medical services.

Overdose of Ecopirin (acetylsalicylic acid) can occur either from taking a single high dose (acute overdose) or from taking lower doses over a long period (chronic or gradual overdose).

Documented Overdose Presentations

System Common Manifestations Severe Manifestations
Auditory/CNS Ringing in the ears (tinnitus), confusion, drowsiness Seizures, coma, brain swelling (cerebral edema)
Respiratory Rapid breathing (hyperventilation), shortness of breath Pulmonary edema, respiratory failure
Gastrointestinal Nausea, vomiting, abdominal pain Gastrointestinal bleeding (less common)
Metabolic Dehydration, fever, shifts in acid-base balance Metabolic acidosis, low blood oxygen level (hypoxia)

Initial symptoms like tinnitus, rapid breathing, and nausea may be mild, but the condition can rapidly worsen to severe toxicity, including central nervous system failure. The severity of poisoning is assessed by measuring the drug level in the blood (serum salicylate concentration) and monitoring the patient's overall clinical condition and acid-base balance. Official labeling warns that packages containing certain high amounts of acetylsalicylic acid have enough drug to seriously harm a child, emphasizing the need for immediate medical intervention in pediatric exposures.

Therapeutic Uses of Ecopirin

What Ecopirin Treats: Main Uses and Benefits

Ecopirin, which contains acetylsalicylic acid (aspirin), is applied across therapeutic domains that require supportive symptom management. The medication is commonly used to help with symptoms related to physical discomfort, inflammatory, or irritative states, and is also applied in contexts involving acute or disruptive episodes, where additional symptomatic support is needed.

It is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms, such as when groups of symptoms appear suddenly or fluctuate. It is also relevant for easing functional strain and tension by managing symptoms that interfere with daily comfort.

Supportive Care and Benefits

This medicine provides supportive care for episodic conditions, assisting with maintaining functional stability during phases of heightened physiological stress. This medication contributes to easing the overall symptom load and helps patients cope more steadily with difficult episodes.

Quick Fact: Applied for Symptomatic Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Ecopirin

Official regulatory guidelines strictly define the eligibility for using Ecopirin (Acetylsalicylic Acid or ASA) based on age, physiological status, and coexisting health conditions.

Absolute Contraindications

Use is contraindicated for several populations, meaning it must not be used:

Condition / Population Status
History of Hypersensitivity to ASA or NSAIDs Contraindicated
Active Peptic Ulcers or GI Bleeding History Contraindicated
Severe Hepatic, Renal, or Heart Failure Contraindicated
Third Trimester of Pregnancy Contraindicated
Children under 16 years of age Contraindicated (Risk of Reye's syndrome)

Eligibility and Restrictions

Ecopirin is typically authorized for use in Adults and Adolescents 16 years and over under standard conditions. Use is not recommended while breastfeeding or during the first and second trimesters of pregnancy. Furthermore, individuals with mild to moderate organ impairment or a history of conditions such as asthma, gout, or controlled hypertension should use the medicine only with caution, as regulatory documents impose restrictions on these populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ecopirin (Acetylsalicylic Acid or ASA) has a documented interaction profile primarily structured around pharmacodynamic effects and the clearance of co-administered medicines, as detailed in regulatory documents.

Documented Interaction Patterns

The co-administration of Ecopirin with certain substances can result in official restrictions, ranging from contraindications to mandatory timing separation, based on authoritative government labeling.

  • Contraindicated Combinations: Co-administration with Methotrexate at high doses (15 mg/week or more) is formally contraindicated. This restriction is due to ASA's effect on reduced renal clearance of Methotrexate, which significantly elevates its plasma concentration and toxicity risk.
  • Bleeding Risk Augmentation: There is an officially documented increased risk of hemorrhage when Ecopirin is co-administered with Anticoagulants (e.g., Warfarin, Heparin), Thrombolytics, or Selective Serotonin Reuptake Inhibitors (SSRIs) due to additive effects on hemostasis.
  • Timing Requirement (Pharmacodynamic Interference): Regulatory labels specify a timing rule for concurrent use with Immediate-Release Ibuprofen. Ibuprofen must be administered at least 8 hours before or 30 minutes after Ecopirin to avoid interference with the antiplatelet effect.
  • Impact on Clearance/Efficacy: ASA reduces the efficacy of Uricosuric Agents (e.g., Probenecid) by interfering with their action. Additionally, co-administration with Systemic Glucocorticoids can reduce Ecopirin plasma levels, with a rebound risk of toxicity upon Glucocorticoid withdrawal.
  • Substance Interactions: Concurrent use with Alcohol (Ethanol) is documented to significantly increase the risk of gastrointestinal hemorrhage.

Mechanism of Action

The mechanism of Acetylsalicylic Acid (ASA) is primarily defined by its action as an irreversible enzyme inhibitor within the Prostanoid Biosynthesis Pathway.

Irreversible Modulation of Platelet Function

ASA functions as an acetylating agent that permanently deactivates the Cyclooxygenase-1 (COX-1) enzyme in circulating blood platelets.

This irreversible blockade prevents platelets from synthesizing Thromboxane A₂ (TXA₂) — a molecular messenger that promotes aggregation. Since platelets are anucleated and cannot synthesize new COX-1 enzyme, this single molecular event supports a prolonged reduction in the platelet's capacity to clump, resulting in a sustained functional defect in platelet activity for its lifespan.

Dual Action on Systemic Prostanoid Pathways

Beyond platelets, the drug also modulates the synthesis of various other prostaglandins in non-platelet cells, engaging mechanisms that modulate systemic signaling pathways involved in thermoregulation and nociception. By limiting the systemic production of these pro-inflammatory mediators, ASA modulates the activity of physiological signaling associated with central and peripheral thermal and nociceptive pathways. This secondary effect is maintained by its continuous but reversible action on COX pathways in tissues capable of enzyme renewal.

Dosage and Administration Information

How to Use Ecopirin (Aspirin Low Dose)

This section outlines the administration instructions for Ecopirin (low-dose aspirin). It is essential to strictly follow the specific dosing prescribed by a physician.

Official Administration Guidelines

Administration Scope Official Instruction
Route of Administration Oral (by mouth)
Dosing Schedule As prescribed by a doctor; typically taken once a day.
Timing in Relation to Meals Take the tablet with or immediately after food.
Preparation Requirements None
Age-Group Rules Not generally recommended for children and adolescents (under 18 years) unless specifically directed by a healthcare provider.
Missed-Dose Rules If a dose is missed, skip the missed dose if it is almost time for the next scheduled dose. Do not take a double dose to make up for a forgotten one.
Special Procedural Conditions The tablet must be swallowed whole with a full glass of water. It must not be crushed, broken, or chewed, as this can disrupt the enteric coating.

Procedural Summary

A clear procedural structure exists for the use of this medicine. The sequence for proper administration involves taking the prescribed dose once daily, ensuring it is consumed with or after food to adhere to labeled gastric protective measures. The final step mandates swallowing the tablet whole with water to maintain the integrity of its formulation, thereby defining the correct oral method. Adherence to the daily dosing schedule, including the specific missed-dose rules, maintains the continuity of the prescribed regimen.

Recent Clinical Evidence

Ecopirin: Recent Clinical Evidence

The research evidence for Ecopirin (Acetylsalicylic Acid, ASA) primarily focuses on studies evaluating its role as an antiplatelet agent. The evidence is drawn from numerous large-scale clinical trials and comprehensive reviews. This overview describes the structure of that research without offering clinical advice or interpreting individual results.

Evidence for Established Cardiovascular Disease (Secondary Prevention)

Research involves large-scale Randomized Controlled Trials (RCTs) and Meta-analyses conducted in adult populations who had previously experienced a major vascular event, such as a heart attack or stroke. Studies monitored outcomes like the recurrence of a nonfatal stroke or a subsequent heart attack. Research reported measurements related to the incidence of these recurrent events in populations with confirmed ischemic heart disease. What remains uncertain is the structure of evidence comparing this medicine against other treatment options in contemporary, long-term protocols, and comparative evidence is lacking for some complex antiplatelet regimens.

Evidence for Preventing a First Cardiovascular Event (Primary Prevention)

A separate body of evidence, derived from multiple large-scale RCTs, research examined the use of the medicine in individuals without a prior history of heart attack or stroke but possessing significant risk factors (e.g., Type 2 diabetes). Findings were mixed across the key primary prevention studies. Studies consistently described a pattern of increased occurrence of major bleeding events compared to placebo groups. This evidence contributes to understanding symptom patterns, but the certainty remains low regarding the generalized application of the findings.

Research on the Enteric-Coated Formulation (Ecopirin's Specific Preparation)

Ecopirin’s specific enteric-coated preparation was studied for how it compares to standard, non-coated aspirin in pharmacodynamic/pharmacokinetic studies. Reports described that the enteric coating is designed to delay absorption. Some research data show patterns related to lower or delayed platelet inhibition measurements in certain individuals using the enteric-coated preparation. Evidence quality varies across studies concerning whether this specific preparation consistently affects gastrointestinal outcomes compared to non-coated forms. The research findings describe group patterns, and the variability observed in study populations means that the research does not determine whether an individual will respond similarly.

Long-Term Data and Patient Groups

Key RCTs utilized long-term follow-up periods, often extending many years. This research provides insight into how patterns evolved in the observed populations. Research was observed in some studies to analyze the effects in different patient groups, such as older adults or individuals with comorbidities. The results apply only to the populations studied; for many specific patient groups, data for certain groups remain insufficient.

Key Studies & References

  1. Antithrombotic Trialists' Collaboration (ATT) meta-analysis: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
  2. Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication | U.S. Preventive Services Task Force (2022 Update)
  3. Pharmacological Efficacy and Gastrointestinal Safety of Different Aspirin Formulations for Cardiovascular Prevention: A Narrative Review

Frequently Asked Questions (FAQ)

Common questions about Ecopirin (FAQ)


Q: What is the main difference between Ecopirin and regular aspirin?

Ecopirin is an enteric-coated formulation of aspirin. According to official product descriptions, this unique coating is designed to prevent the tablet from dissolving in the acidic environment of the stomach. The goal of the coating is to delay the release of the medicine until it reaches the small intestine, unlike regular, non-coated aspirin which dissolves much sooner.


Q: Do you need a prescription to buy Ecopirin?

Regulatory documents indicate that low-dose aspirin products, including many enteric-coated forms, are often categorized as over-the-counter (OTC) medicines. However, certain higher-dose formulations of aspirin are classified as prescription medicines, requiring a healthcare provider's authorization.


Q: Is Ecopirin used as a pain reliever?

Aspirin, the active ingredient in Ecopirin, is classified by regulatory authorities as a nonsteroidal anti-inflammatory drug (NSAID). While its main purpose is to modulate platelet activity, the drug is also indicated in official regulatory sources for the temporary relief of minor aches and pains.


Q: How long does it usually take for Ecopirin to start working?

Due to the enteric coating, the absorption of the medicine is delayed compared to non-coated aspirin. Regulatory pharmacokinetic reports indicate that the onset of the antiplatelet effect—the intended blood-thinning action—can take several hours after taking a single dose. This effect is designed to be maintained through a consistent daily regimen.


Q: Are there any dietary restrictions while taking Ecopirin?

Official regulatory labels have not established specific drug-food interactions for aspirin. Official administration guidelines often mention that the tablet may be taken with or immediately after food. This recommendation is provided to help reduce potential irritation to the stomach lining.


Q: What happens if I accidentally take two doses of Ecopirin?

Taking more than the quantity that was prescribed increases the risk of serious side effects like stomach bleeding. Regulatory warnings state that serious side effects require immediate attention from a healthcare provider or a poison control center.


Q: Does Ecopirin affect blood pressure?

Ecopirin is not primarily indicated as a treatment for high blood pressure. Official information notes that individuals with existing high blood pressure are among those for whom caution and professional oversight are recommended before beginning use. Research has examined relationships between aspirin use and blood pressure patterns.


Q: Is Ecopirin the same as other blood thinners?

Ecopirin is classified as an antiplatelet agent, a type of medicine that helps prevent blood clots. It is commonly included in the general category of 'blood thinners' by patients. However, it is chemically and functionally distinct from anticoagulants (like Warfarin), which work through different mechanisms in the blood clotting cascade.


Q: Are there any long-term side effects of taking Ecopirin?

Official product information, including patient safety guides, states that long-term use of aspirin is associated with a risk of developing serious gastrointestinal ulcers and bleeding. This bleeding risk is described as being related to the dosage used. Long-term follow-up in studies also reports serious bleeding events in the observed populations.


Q: Can Ecopirin interact with herbal supplements?

Official sources caution that aspirin may interact with certain herbal remedies or other supplements. Official guidance emphasizes the importance of a healthcare professional being informed about all non-prescription and herbal products being used, as some supplements have been noted to potentially increase the general risk of bleeding.


Q: Is Ecopirin safe for people who have had stomach ulcers?

Ecopirin is contraindicated (must not be used) in patients who have active peptic ulcers or active bleeding. Regulatory warnings indicate that a prior history of stomach problems, such as ulcers or bleeding events, increases the chance of severe stomach bleeding, making professional oversight necessary.


Q: What kind of research supports the use of Ecopirin for its main purpose?

The use of aspirin is supported by a large volume of research, including numerous Randomized Controlled Trials (RCTs) and meta-analyses. These studies are structured to assess the medicine's effect in reducing the recurrence of major vascular events, such as heart attack or stroke, in specific patient populations.


Q: Is it true that Ecopirin can be used to prevent certain cancers?

Some authoritative health bodies have acknowledged research examining the use of low-dose aspirin for the prevention of colorectal cancer in specific adult populations. However, this cancer prevention effect is not generally listed as a primary regulatory indication on official drug labels.


Q: Does Ecopirin have any known interaction with vitamins?

Official regulatory reports indicate that aspirin may potentially interfere with the action of Vitamin K in the body, which is essential for blood coagulation. Individuals with a Vitamin K deficiency are identified in official warnings as a group for whom use requires professional oversight.


Q: Why is the typical dose of Ecopirin so low (e.g., 81 mg or 100 mg)?

The low-dose range is used because it is sufficient to target the antiplatelet effect. This amount achieves complete and persistent inhibition of the COX-1 enzyme in platelets, which is the mechanism used to reduce their ability to clump together.


Q: Does Ecopirin make you gain or lose weight?

Regulatory documents listing common and uncommon side effects of aspirin do not typically include weight gain or weight loss as a documented adverse reaction associated with the drug's use in standard regimens.


Q: What is the onset of action for the antiplatelet effect of Ecopirin?

The antiplatelet effect, which is the medicine's main action on blood flow, is achieved within a timeframe that can range from 70 minutes up to several hours following administration of the oral dose. The effect is considered permanent for the life of the platelet that was exposed.


Q: Can Ecopirin cause hearing issues or tinnitus?

Official safety information describes that if ringing in the ears (tinnitus) or any loss of hearing occurs, the product's use should be discontinued, and a healthcare professional should be contacted. These symptoms are listed as potential signs of toxicity associated with the medicine.


Q: Is it necessary to take Ecopirin at the same time every day?

Regulatory documents describe the standard use of the medicine as a once-daily regimen. Adherence to a consistent daily regimen is necessary to maintain the irreversible antiplatelet effect over time. The necessity of taking the medicine at a precise time daily is a consideration for professional oversight to maintain a consistent regimen.


Q: How is the effectiveness of Ecopirin measured in studies?

The effectiveness of aspirin is measured in clinical trials by monitoring critical outcomes such as the recurrence of vascular events (heart attack, stroke) in the study population. Laboratory effectiveness is also assessed by testing for the degree of platelet inhibition, often reported using specific measurement units.


Q: Does Ecopirin interact with common cold or flu remedies?

Yes, regulatory documents caution that many common cold and flu remedies may contain other NSAIDs (like ibuprofen). Taking aspirin with other NSAIDs can increase the risk of bleeding or potentially interfere with aspirin's intended actions, and regulatory warnings caution against co-administration.


Q: Are there different brands of the same enteric-coated aspirin as Ecopirin?

Yes, the active ingredient in Ecopirin is Acetylsalicylic Acid. This compound is sold by many pharmaceutical manufacturers under different brand names as an enteric-coated tablet, once the product has been approved as a generic equivalent by regulatory bodies.


Q: Does Ecopirin expire, and can I take an expired tablet?

Ecopirin, like all medicines, does expire. Official instructions state that the medicine must not be used after the expiration date printed on the label or packaging. Expired aspirin may sometimes be identifiable by a strong vinegar-like smell.


Q: Why do official documents mention the need for a maintenance dose of Ecopirin?

The term maintenance dose refers to the regular, ongoing low amount of the medicine needed to sustain the antiplatelet effect over the long term. This daily amount is required to continually inhibit new platelets formed by the body, ensuring consistent action following any necessary initial treatment period.


Q: Does Ecopirin interact with antacids?

Regulatory sources have advised that using combination products that contain both aspirin and antacids may increase the risk of serious bleeding. Simple antacids may also potentially alter the integrity of the enteric coating, which could change the medicine’s absorption profile.

How should Ecopirin be stored and disposed of?

How to Store and Dispose of Ecopirin?

Ecopirin (Acetylsalicylic Acid, enteric-coated tablet) must be stored and handled according to its official regulatory profile to maintain stability.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically below 25°C or 30°C.
Protection Protect from moisture, light, and do not freeze.
Container Keep the tablets in the original container and keep it tightly closed to protect the enteric coating.
Safety The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Regulatory agencies require that unused or expired Ecopirin not be disposed of via household waste or wastewater. The product must be discarded in compliance with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ecopirin found in:

A-Z Index: